#117321
Re: Farmas USA
EXEL
Exelixis’ Partner Ipsen Announces Health Canada’s Approval of CABOMETYX® (cabozantinib) Tablets for the Treatment of Patients With Previously Treated Advanced Hepatocellular Carcinoma
Exelixis’ Partner Ipsen Announces Health Canada’s Approval of CABOMETYX® (cabozantinib) Tablets for the Treatment of Patients With Previously Treated Advanced Hepatocellular Carcinoma
«Después de nada, o después de todo/ supe que todo no era más que nada.»